Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2021
Reporting Period: Immediate event reporting for transactions executed on May 6, 2021, with an expected closing date of May 13, 2021.
Key Financial Metrics and Transaction Details
This filing details a significant capital structure restructuring involving debt exchange, new debt issuance, and equity repurchases. No revenue, profit, or operating cash flow metrics are provided in this specific filing.
- Debt Exchange: Exchange of approximately $82.1 million of existing 3.75% Convertible Senior Notes due 2022 for $97.1 million of new 3.75% Convertible Senior Notes due 2026.
- New Debt Issuance (Subscription): Sale of $2.9 million aggregate principal amount of new notes to qualified investors.
- Equity Repurchase: Agreement to repurchase approximately 3.1 million shares of common stock at $4.51 per share (totaling approximately $14.0 million).
- New Credit Facility:
- Term Loan: $80 million, 5-year maturity (May 6, 2026).
- Revolving Credit: $40 million, 5-year maturity (May 6, 2026).
- Interest Rate: LIBOR + 2.50% to 3.25% (based on leverage ratio), with a 0.50% LIBOR floor.
- Collateral: Secured by first-priority liens on substantially all assets of the Company and TomoTherapy Incorporated.
- Debt Termination: Proceeds from the new Credit Facility and cash on hand will be used to repay and terminate existing credit facilities on May 13, 2021.
Material Changes Versus Prior Period
The filing represents a material change in the Company's capital structure and debt obligations:
- Extension of Maturity: The Company is extending the maturity of a significant portion of its convertible debt from 2022 to 2026.
- Debt Refinancing: Existing credit facilities with MidCap Financial Trust are being terminated and replaced by a new senior secured credit agreement with Silicon Valley Bank and other lenders.
- Share Count Reduction: The Company is reducing its outstanding share count by approximately 3.1 million shares through the repurchase program.
- Liquidity Impact: The transaction is designed to improve liquidity and extend the debt maturity profile, though it increases total debt principal outstanding in the short term due to the exchange premium and new term loan.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company anticipates the Transactions will close on May 13, 2021. Following the closing, approximately $2.9 million of the 2022 notes will remain outstanding. The repurchase of shares is intended to facilitate the exchange and may support the market price of the common stock or new notes.
Risks and Contingencies:
- Closing Conditions: The Subscription is conditioned on the closing of the Exchange.
- Covenants: The new Credit Agreement imposes strict financial covenants, including a Fixed Charge Coverage Ratio and a Consolidated Senior Net Leverage Ratio. Failure to meet these could trigger an event of default.
- Prepayment Penalties: Prepayment of the Term Loan Facility incurs a 1% fee.
- Early Maturity: The new Credit Facilities may mature earlier than May 2026 if certain conditions are not met, including if the new notes mature prior to their stated maturity.
- Unregistered Securities: The new notes are being issued in a private placement relying on Section 4(a)(2) of the Securities Act.
Important Facts for Investor Verification
- Verify the final closing date of the transactions (expected May 13, 2021) and confirm the exact amount of 2022 notes remaining outstanding.
- Review the specific definitions of "Consolidated Senior Net Leverage Ratio" and "Fixed Charge Coverage Ratio" in the new Credit Agreement to assess covenant compliance risk.
- Confirm the total cash outflow required for the 3.1 million share repurchase and its impact on immediate liquidity.
- Monitor the interest rate environment, as the new debt is tied to LIBOR with a 0.50% floor, affecting future interest expense.
- Check subsequent filings for the full text of the Credit Agreement and the specific terms of the Exchange and Subscription Agreements filed as Exhibits 10.1 and 10.2.